Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 13 | 2025 | 160 | 6.450 |
Why?
|
| Lung Neoplasms | 17 | 2024 | 695 | 4.460 |
Why?
|
| Thoracic Surgical Procedures | 7 | 2025 | 42 | 3.530 |
Why?
|
| Thoracic Surgery | 7 | 2025 | 76 | 3.270 |
Why?
|
| Thoracic Surgery, Video-Assisted | 7 | 2025 | 61 | 2.710 |
Why?
|
| Esophageal Neoplasms | 5 | 2024 | 86 | 2.530 |
Why?
|
| Surgeons | 4 | 2023 | 182 | 2.020 |
Why?
|
| Thoracic Wall | 3 | 2025 | 21 | 1.850 |
Why?
|
| Pleural Neoplasms | 5 | 2025 | 19 | 1.840 |
Why?
|
| Pneumonectomy | 6 | 2024 | 116 | 1.500 |
Why?
|
| Esophagectomy | 4 | 2024 | 48 | 1.380 |
Why?
|
| Thoracotomy | 4 | 2025 | 47 | 1.240 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 174 | 1.200 |
Why?
|
| Mediastinal Neoplasms | 2 | 2025 | 21 | 1.200 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 321 | 1.170 |
Why?
|
| Databases, Factual | 8 | 2024 | 856 | 1.090 |
Why?
|
| Conversion to Open Surgery | 2 | 2025 | 14 | 0.940 |
Why?
|
| Thoracic Neoplasms | 1 | 2025 | 14 | 0.930 |
Why?
|
| Mesothelioma | 4 | 2014 | 28 | 0.910 |
Why?
|
| Thoracoscopy | 1 | 2025 | 27 | 0.910 |
Why?
|
| Anastomotic Leak | 2 | 2023 | 35 | 0.880 |
Why?
|
| Precision Medicine | 1 | 2025 | 124 | 0.840 |
Why?
|
| Suture Techniques | 1 | 2024 | 99 | 0.840 |
Why?
|
| Humans | 51 | 2025 | 64243 | 0.820 |
Why?
|
| Esophageal Achalasia | 1 | 2023 | 33 | 0.770 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2023 | 41 | 0.760 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2022 | 4 | 0.750 |
Why?
|
| Herpes Simplex | 1 | 2022 | 50 | 0.720 |
Why?
|
| GPI-Linked Proteins | 5 | 2014 | 40 | 0.690 |
Why?
|
| Molecular Imaging | 2 | 2011 | 52 | 0.670 |
Why?
|
| Clinical Competence | 2 | 2024 | 728 | 0.650 |
Why?
|
| Unnecessary Procedures | 1 | 2020 | 49 | 0.640 |
Why?
|
| Radiation Dosage | 1 | 2020 | 138 | 0.610 |
Why?
|
| Biomedical Research | 1 | 2021 | 270 | 0.560 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 1669 | 0.560 |
Why?
|
| Retrospective Studies | 15 | 2024 | 6726 | 0.560 |
Why?
|
| Societies, Medical | 4 | 2024 | 381 | 0.520 |
Why?
|
| Metastasectomy | 1 | 2016 | 4 | 0.480 |
Why?
|
| Treatment Outcome | 9 | 2024 | 5691 | 0.470 |
Why?
|
| Stomach | 2 | 2012 | 87 | 0.440 |
Why?
|
| Dyspnea | 2 | 2012 | 124 | 0.440 |
Why?
|
| Biomarkers, Tumor | 3 | 2013 | 512 | 0.430 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 2238 | 0.420 |
Why?
|
| Disease Management | 1 | 2016 | 237 | 0.420 |
Why?
|
| Anastomosis, Surgical | 2 | 2024 | 116 | 0.410 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 529 | 0.400 |
Why?
|
| Tumor Burden | 2 | 2021 | 73 | 0.390 |
Why?
|
| Lymph Nodes | 2 | 2011 | 229 | 0.390 |
Why?
|
| Postoperative Complications | 3 | 2021 | 1294 | 0.390 |
Why?
|
| Diaphragmatic Eventration | 1 | 2012 | 2 | 0.380 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2012 | 3 | 0.380 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2024 | 126 | 0.380 |
Why?
|
| Pneumopericardium | 1 | 2012 | 3 | 0.370 |
Why?
|
| Gastric Fistula | 1 | 2012 | 4 | 0.370 |
Why?
|
| Puerperal Disorders | 1 | 2012 | 16 | 0.370 |
Why?
|
| Epithelioid Cells | 1 | 2012 | 4 | 0.370 |
Why?
|
| Pericardium | 1 | 2012 | 35 | 0.370 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 195 | 0.360 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 60 | 0.360 |
Why?
|
| Lymphatic Metastasis | 2 | 2011 | 93 | 0.360 |
Why?
|
| Lung | 4 | 2021 | 964 | 0.350 |
Why?
|
| Cesarean Section | 1 | 2012 | 104 | 0.340 |
Why?
|
| Surgical Flaps | 1 | 2012 | 116 | 0.340 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 210 | 0.330 |
Why?
|
| Models, Animal | 1 | 2011 | 240 | 0.330 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 46 | 0.330 |
Why?
|
| Oximetry | 1 | 2010 | 48 | 0.330 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2010 | 89 | 0.310 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 355 | 0.310 |
Why?
|
| Pneumothorax | 2 | 2024 | 50 | 0.300 |
Why?
|
| Female | 20 | 2025 | 33351 | 0.300 |
Why?
|
| Esophagus | 2 | 2023 | 49 | 0.290 |
Why?
|
| Research Support as Topic | 1 | 2009 | 42 | 0.290 |
Why?
|
| Health Care Reform | 1 | 2009 | 88 | 0.290 |
Why?
|
| Bronchogenic Cyst | 1 | 2008 | 2 | 0.290 |
Why?
|
| Science | 1 | 2009 | 34 | 0.280 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 13 | 0.280 |
Why?
|
| Pancreatic Neoplasms | 2 | 2010 | 349 | 0.280 |
Why?
|
| Epidermal Cyst | 1 | 2008 | 11 | 0.280 |
Why?
|
| Splenic Diseases | 1 | 2008 | 14 | 0.280 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 50 | 0.270 |
Why?
|
| Insurance, Health | 1 | 2009 | 151 | 0.270 |
Why?
|
| Pancreatic Diseases | 1 | 2008 | 38 | 0.270 |
Why?
|
| Choristoma | 1 | 2008 | 23 | 0.270 |
Why?
|
| Internship and Residency | 2 | 2025 | 808 | 0.260 |
Why?
|
| Middle Aged | 14 | 2024 | 17899 | 0.260 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 207 | 0.260 |
Why?
|
| Quality Improvement | 2 | 2022 | 455 | 0.250 |
Why?
|
| Aged | 13 | 2024 | 14648 | 0.250 |
Why?
|
| Spleen | 1 | 2008 | 482 | 0.250 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2006 | 12 | 0.240 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 666 | 0.240 |
Why?
|
| Prognosis | 6 | 2022 | 1769 | 0.230 |
Why?
|
| Computer-Assisted Instruction | 1 | 2006 | 80 | 0.230 |
Why?
|
| Male | 15 | 2025 | 30295 | 0.220 |
Why?
|
| Animals | 10 | 2025 | 20962 | 0.220 |
Why?
|
| Urinary Bladder | 1 | 2024 | 45 | 0.220 |
Why?
|
| Emergencies | 1 | 2025 | 121 | 0.220 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2006 | 160 | 0.220 |
Why?
|
| Aorta | 1 | 2024 | 110 | 0.210 |
Why?
|
| Swine | 1 | 2024 | 394 | 0.200 |
Why?
|
| Diagnosis, Differential | 4 | 2012 | 984 | 0.200 |
Why?
|
| Consensus | 1 | 2024 | 185 | 0.200 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2023 | 22 | 0.200 |
Why?
|
| Curriculum | 2 | 2024 | 606 | 0.200 |
Why?
|
| Benchmarking | 2 | 2023 | 134 | 0.200 |
Why?
|
| Time Factors | 3 | 2024 | 3724 | 0.200 |
Why?
|
| General Surgery | 1 | 2006 | 214 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 4 | 2022 | 278 | 0.200 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2023 | 74 | 0.190 |
Why?
|
| Adult | 12 | 2025 | 17117 | 0.190 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1211 | 0.190 |
Why?
|
| Bronchoscopes | 1 | 2022 | 11 | 0.190 |
Why?
|
| Endoscopy | 1 | 2023 | 112 | 0.190 |
Why?
|
| Simplexvirus | 1 | 2022 | 26 | 0.180 |
Why?
|
| Virtual Reality | 1 | 2022 | 15 | 0.180 |
Why?
|
| Bronchoscopy | 1 | 2022 | 90 | 0.180 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 350 | 0.180 |
Why?
|
| Learning | 1 | 2023 | 184 | 0.170 |
Why?
|
| Parents | 1 | 2025 | 395 | 0.170 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 5 | 0.170 |
Why?
|
| Carbon Monoxide | 1 | 2021 | 63 | 0.170 |
Why?
|
| Simulation Training | 1 | 2022 | 66 | 0.170 |
Why?
|
| Robotics | 1 | 2022 | 87 | 0.170 |
Why?
|
| Data Warehousing | 1 | 2020 | 7 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 259 | 0.160 |
Why?
|
| Medicare | 1 | 2024 | 611 | 0.160 |
Why?
|
| United States | 5 | 2024 | 7923 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2020 | 104 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 374 | 0.150 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1102 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 358 | 0.150 |
Why?
|
| Program Evaluation | 1 | 2020 | 490 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2012 | 276 | 0.130 |
Why?
|
| Diagnostic Imaging | 2 | 2011 | 266 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1681 | 0.130 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 2478 | 0.130 |
Why?
|
| Recurrence | 2 | 2024 | 650 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 457 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 109 | 0.110 |
Why?
|
| Mice | 4 | 2013 | 11003 | 0.110 |
Why?
|
| Gallbladder Diseases | 1 | 2015 | 27 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 40 | 0.110 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2015 | 50 | 0.110 |
Why?
|
| Rats | 2 | 2025 | 2005 | 0.110 |
Why?
|
| Patient Selection | 2 | 2015 | 487 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2014 | 1001 | 0.110 |
Why?
|
| Drainage | 2 | 2012 | 155 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 5520 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 102 | 0.100 |
Why?
|
| Cell Movement | 2 | 2013 | 466 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 291 | 0.100 |
Why?
|
| Rupture, Spontaneous | 1 | 2012 | 21 | 0.090 |
Why?
|
| Esophageal Atresia | 1 | 2012 | 9 | 0.090 |
Why?
|
| Sternotomy | 1 | 2012 | 13 | 0.090 |
Why?
|
| Laparotomy | 1 | 2012 | 53 | 0.090 |
Why?
|
| Methods | 1 | 2011 | 40 | 0.090 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 30 | 0.090 |
Why?
|
| Osteopontin | 1 | 2011 | 21 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2012 | 212 | 0.090 |
Why?
|
| Chest Pain | 1 | 2012 | 84 | 0.090 |
Why?
|
| Oncolytic Viruses | 1 | 2011 | 8 | 0.090 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2011 | 12 | 0.090 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 39 | 0.090 |
Why?
|
| Pleurodesis | 1 | 2011 | 9 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 209 | 0.090 |
Why?
|
| Chest Tubes | 1 | 2011 | 17 | 0.090 |
Why?
|
| Reoperation | 1 | 2012 | 291 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 297 | 0.080 |
Why?
|
| Sus scrofa | 1 | 2010 | 30 | 0.080 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 68 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 42 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 544 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2012 | 614 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 645 | 0.080 |
Why?
|
| Young Adult | 3 | 2024 | 4776 | 0.080 |
Why?
|
| Palliative Care | 2 | 2011 | 239 | 0.080 |
Why?
|
| Acute Disease | 1 | 2012 | 672 | 0.080 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2010 | 1 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2012 | 668 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 891 | 0.080 |
Why?
|
| Intestines | 1 | 2010 | 169 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 306 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 625 | 0.070 |
Why?
|
| Politics | 1 | 2009 | 37 | 0.070 |
Why?
|
| India | 1 | 2009 | 158 | 0.070 |
Why?
|
| Thigh | 1 | 2008 | 27 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 783 | 0.070 |
Why?
|
| Kidney | 1 | 2010 | 455 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 67 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 220 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2014 | 802 | 0.070 |
Why?
|
| Survival Rate | 2 | 2024 | 859 | 0.060 |
Why?
|
| Length of Stay | 2 | 2024 | 818 | 0.060 |
Why?
|
| Apoptosis | 1 | 2012 | 1094 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1551 | 0.060 |
Why?
|
| Diaphragm | 1 | 2025 | 25 | 0.060 |
Why?
|
| Feedback | 1 | 2025 | 93 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2012 | 2046 | 0.060 |
Why?
|
| Pleura | 1 | 2024 | 12 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2012 | 1118 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2025 | 153 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2014 | 517 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2014 | 526 | 0.050 |
Why?
|
| Suction | 1 | 2022 | 35 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 423 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 91 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 318 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1272 | 0.040 |
Why?
|
| Neoplasms | 1 | 2011 | 1392 | 0.040 |
Why?
|
| Water | 1 | 2022 | 314 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 1494 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 218 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2022 | 482 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 2616 | 0.040 |
Why?
|
| Pregnancy | 1 | 2025 | 2370 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2737 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2015 | 3315 | 0.030 |
Why?
|
| Chimerism | 1 | 2014 | 12 | 0.030 |
Why?
|
| Operative Time | 1 | 2015 | 91 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2014 | 147 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 167 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 249 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 239 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 627 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 22 | 0.020 |
Why?
|
| Mucins | 1 | 2012 | 26 | 0.020 |
Why?
|
| Camptothecin | 1 | 2012 | 29 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 761 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 91 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2012 | 144 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2012 | 64 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 162 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 144 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 872 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 199 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 851 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 930 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 65 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1365 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1130 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1019 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 587 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1176 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 2604 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 5339 | 0.010 |
Why?
|